$BGNE Initiates Two Global Phase 3 FrontLine Clinical Trials of Tislelizumab in Patients with Gastric Cancer and in Patients with Esophageal Cancer httpsglobenewswire.comnewsrelease2018121716677400enBeiGeneInitiatesTwoGlobalPhase3Fron

$BGNE Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer https://globenewswire.com/news-release/2018/12/17/1667740/0/en/BeiGene-Initiates-Two-Global-Phase-3-Fron

06:04 EST 17 Dec 2018 | Odi Bruckman

$BGNE Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer https://globenewswire.com/news-release/2018/12/17/1667740/0/en/BeiGene-Initiates-Two-Global-Phase-3-Front-Line-Clinical-Trials-of-Tislelizumab-in-Patients-with-Gastric-Cancer-and-in-Patients-with-Esophageal-Cancer.html …

More From BioPortfolio on "$BGNE Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer https://globenewswire.com/news-release/2018/12/17/1667740/0/en/BeiGene-Initiates-Two-Global-Phase-3-Fron"